Chaired by Director Rivka (Rashieda) Gluck, SAB Aims to Advance Clinical and Industrial Applications of Anti-Biofilm Technology
WINNIPEG, Manitoba, Sept. 24, 2018 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX-V:KNE, OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”), today announced the formation of a Scientific Advisory Board (SAB), chaired by Kane Biotech Board Director Rivka Gluck, and will work closely with senior management to advance the Company’s integration and scope of clinical applications of its patented anti-microbial technology.
The SAB, comprised of world-leading experts in human health and industrial biotech will also include the appointments of Gordon Guay, Ph.D., and Robert Huizinga, Ph.D. The SAB will work closely with Kane Biotech management as it actively identifies and explores the potential of Kane’s intellectual patent portfolio to positively impact untapped applications in industrial and human health applications.
Marc Edwards, Kane Biotech’s Chief Executive Officer, stated, “Dr. Guay has been instrumental as a Research Fellow to develop and launch many commercial products at Proctor & Gamble and Gillette. We’re proud to have Gordon on our Scientific Advisory Board to advise on best implementing our biofilm technology in many large-scale industrial and consumer applications. Along with Rivka Gluck, Dr. Huizinga carries a wealth of management and leadership experience in the biotech and pharmaceutical industries and, along with clinical experience, brings a powerful combination of human and animal health experience.”
About Rivka Gluck
Ms. Gluck has over 25 years of pharmaceutical and biotech industry experience and currently serves as Senior Vice President of Global Clinical Operations at Aurinia Pharmaceuticals Inc. where she has been with the company since January 2016. She was Vice President of Clinical Operations at Qu Biologics Inc., where she led the clinical development for their platform immunotherapeutic treatments and prior to that, served as Vice President and Head of Global Clinical Operations at Vifor Pharmaceuticals, based in Zurich Switzerland. In her career, Ms. Gluck served in increasingly senior positions at major pharmaceutical companies including Novartis, Organon, and GSK.
About Gordon Guay, Ph.D.
Gordon has over twenty-five years of experience in R&D and new product development. He has worked as a Research Fellow at Proctor and Gamble serving as the lead scientist within a range of different P&G business units including: Oral-B, Gillette, Olay, Right Guard, CoverGirl, Max Factor and Duracell. Gordon has received over 11 international awards for new products developed while he is working at P&G. Prior to P&G, Gordon was the Director of Research at Catalytic Antibodies Inc.
Gordon received a Ph.D. in molecular genetics from the University of Illinois. His research focused on bacterial resistance to sulfonamides. He also conducted post-Doctoral work at Lederle Laboratories on substrate specificity of tetracycline efflux pumps.
About Robert Huizinga, PhD RN, CNeph(C)
Rob has more than 25 years of pharmaceutical development experience. He has managed the global clinical development of voclosporin since 2002 where he was with Isotechnika Pharma, Inc. prior to its merger with Aurinia in 2013. Before joining industry, Rob was an investigator in nephrology and transplantation clinical trials at the University of Alberta Division of Nephrology & Immunology, where he was involved in more than 60 clinical trials from Phase I through Phase IV and the successful development of numerous compounds including CellCept®, Neoral®, Prograf®, Aranesp® and Simulect®. He has acted as a consultant to nephrology and transplantation pharmaceutical companies, has lectured extensively and is recognized as an expert in immunosuppression drug development. Rob has numerous articles published in leading medical journals, including the New England Journal of Medicine, Lancet and the American Journal of Transplantation. He is a member of many professional societies related to nephrology, transplantation, and nursing and is the founder of RenalPro, a moderated forum for renal professionals.
Rob holds a M.Sc. in Medicine (Epidemiology) from the University of Alberta, a PhD in Organizational Leadership from Regent University, is certified in Nephrology and a member of Sigma Theta Tau (Honor Society of Nursing). He holds a certificate in leadership from EQUIP Leadership.
About Kane Biotech
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.
The Corporation has a portfolio of biotechnologies, intellectual property (75 patents and patents pending, trade secrets and trademarks) and products developed by the Corporation’s own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex®, bluestem™, AloSera™, coactiv+™ and Kane® are trademarks of Kane Biotech Inc. The Corporation is listed on the TSX Venture Exchange under the symbol “KNE” and on the OTCQB Venture Market under the symbol “KNBIF”.
|For more information, please visit www.kanebiotech.com or contact:|
|Chief Financial Officer|
|Kane Biotech Inc.|
|+1 (204) email@example.com|
|Vice President – Investor Relations|
|+1 (646) firstname.lastname@example.org|
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedar.com. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.
These risks and uncertainties should be considered carefully undue reliance should not be placed on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot provide assurance that actual results will be consistent with these forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statement.